A Phase 4 interventional study of a second infusion of ZOL when crosslaps levels reach 300 pg/mL and a rescue second infusion at month-12 (standard traitment) in Postmenopausal Osteoporosis, sponsored by University Hospital, Toulouse. Recruiting at 17 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University Hospital, Toulouse · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Osteoporosis, Postmenopausal with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Osteoporosis, Postmenopausal · France.
Among the 22 studies in Osteoporosis, Postmenopausal with a site in France, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 4, and was the 22nd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →3 of the 22 studies in Osteoporosis, Postmenopausal with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 50–65 · Women only
University Hospital, Clermont-Ferrand · Sites in France
Ages 50+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 719 across the 19 interventional studies, 152 across the 3 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoporosis, Postmenopausal with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05228262University Hospital, Clermont-FerrandVascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis | 2027-02-01 |
| NCT05575167424 General Military HospitalSingle or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) | 2027-07 |
| NCT05571514Centre Hospitalier Universitaire de Saint EtienneStudy of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Osteoporosis, Postmenopausal with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.
Denosumab (Dmab) is a potent and validated treatment for postmenopausal osteoporosis. However, its withdrawal, especially after reaching therapeutic target, is associated with a rebound phenomenon characterized by: (i) an increase in bone turnover markers levels usually within first 6 months off-treatment, (ii) a decrease in BMD, and (iii) an unexpected increased risk of (multiple) vertebral fractures. Although current experts' recommendations propose a post-Dmab bisphosphonates therapy (such as ZOL) to mitigate rebound phenomenon, the optimal strategy is still matter of debate. Data suggesting a protective effect with bisphosphonates (1 infusion of ZOL or weekly alendronate) are scarce, with discrepancies, and highlight that a substantial proportion of patients experiences rebound-related bone loss despite bisphosphonate therapy. Crosslaps, a bone turnover maker, are available for daily clinical practice and reflect the antiresorptive activity of anti-resorptive drugs such as bisphosphonates. Investigator hypothesize that monitoring crosslaps levels, can help to identify patients requiring more intensive bisphosphonate (additional ZOL infusion) therapy to control the post-Dmab rebound phenomenon.
Investigator propose to compare 2 strategies for Dmab withdrawal in postmenopausal osteoporosis: a standard treatment control group treated with a single ZOL infusion versus a biomarker-guided ZOL group with an additional ZOL infusion in case of insufficient inhibition of bone resorption according to crosslaps.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
Drug: a second infusion of ZOL when crosslaps levels reach 300 pg/mL
Potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
Drug: a rescue second infusion at month-12 (standard traitment)
a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
Maintain lumbar bone mineral density (BMD) after 1 year of ZOL
The proportion of patients who failed to maintain lumbar BMD after 1 year of ZOL according to the Least Significant Change (LSC) criterion
Time frame: 1 year after inclusion
Maintain hip bone mineral density (BMD) after 1 year of ZOL
The proportion of patients who failed to maintain hip BMD after 1 year of ZOL according to the Least Significant Change (LSC) criterion
Time frame: 1 year after inclusion
the changes in hip and lumbar BMD from baseline
the changes in hip and lumbar BMD from baseline to 1 year, and from year 1 to year 2 after ZOL, according to the Least Significant Change (LSC) criterion
Time frame: Day 0, 1 year after inclusion, 2 year after inclusion
the changes from baseline in bone turnover markers
Bone turnover markers is a composite measure derived from crosslaps, bone alkaline phosphatase, osteocalcin, amino-terminal propeptide of type 1 procollagen, TRAP5b, dickkopf 1, sclerostin
Time frame: 1 year after inclusion, 2 year after inclusion
morphometric vertebral fractures
the number of morphometric vertebral fractures measured by vertebral fracture assessment (VFA) or X-rays, of clinical vertebral fractures and of clinical peripheral fractures
Time frame: 1 year after inclusion, 2 year after inclusion
Patients requiring a second ZOL
the proportion of patients requiring a second ZOL infusion across groups.
Time frame: 1 year after inclusion, 2 year after inclusion
Relation between biomarker values and densitometry evolution
the relation is defined by biomarker values (cross laps) and densitometry evolution measured bu osteodensitometry
Time frame: 3, 6, 9, 12 months after inclusion
Relation between biomarker values and appearance of new vertebral fracture
the relation is defined by biomarker values (cross laps) and appearance of new vertebral fracture measured by VFA or X-rays
Time frame: 3, 6, 9, 12 months after inclusion
Started Oct 2025 (actual). Primary completion is estimated for Oct 2030, 60 months after the start.
Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
University Hospital, Toulouse →